This study assessed the agreement between infrared tympanic membrane (TM), axillary, corrected axillary (+0.5 degrees C), oral, and corrected oral (+0.3 degrees C) to rectal thermometry as reference standard in neutropenic adults. The sensitivity and specificity of the mentioned thermometries in detecting rectal fever (> or =38 degrees C) were also analysed.
Honeycomb with good mechanical properties and low density are the top priorities in
material selection. Therefore, the facesheet thickness is a factor that contributes to it
as it made up most of the weight in the structure. Appropriate thickness can optimize
the mechanical performance. However, the sandwich composite may associate to high
density if the facesheet is of high thickness yet deteriorate the mechanical properties
as an overall. As the facesheet is attached to the sandwich structure via matrix, the
peeling properties for various facesheet thickness is investigated. The facesheet
thickness in terms of one to five layers are glued to the rubber wood core. The
structures are tested for its peeling strength under vertical 90° test according to the
ASTM standard. The optimal number of facesheet with good peeling strength is
discussed
Despite the excellent efficacy and improved clinical responses obtained with imatinib mesylate (IM), development of resistance in a significant proportion of chronic myeloid leukemia (CML) patients on IM therapy have emerged as a challenging problem in clinical practice. Resistance to imatinib can be due to heterogeneous array of factors involving BCR/ABL-dependent and BCR/ABL-independent pathways. Although BCR/ABL mutation is the major contributory factor for IM resistance, reduced bio-availability of IM in leukemic cells is also an important pharmacokinetic factor that contributes to development of resistance to IM in CML patients. The contribution of polymorphisms of the pharmacogenes in relation to IM disposition and treatment outcomes have been studied by various research groups in numerous population cohorts. However, the conclusions arising from these studies have been highly inconsistent. This review encompasses an updated insight into the impact of pharmacogenetic variability on treatment response of IM in CML patients.